July 9, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Eagle Announces New Patent Issued forBendamustine Hydrochloride Injection in the U.S.
TOKYO, Japan, July 9, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,")announced today that its U.S. partner, Eagle Pharmaceuticals, Inc. (Headquarters: Woodcliff Lake, NJ,“Eagle”) announced on July 3, 2018 that an additional patent has been issued related to BENDEKA ®
by the United States Patent and Trademark Office (USPTO). Eagle’s bendamustine liquid
formulations are now protected by 14 patents expiring from 2026 to 2033. Under the terms of thelicense agreement concluded with Eagle in September 2017（*）, SymBio has an exclusive license todevelop , market and sell Eagle’s bendamustine hydrochloride ready-to-dilute (RTD) and rapid
infusion (RI) injection products in Japan.
For Eagle's full press release , please visit the company's website.
http://investor.eagleus.com/
With regard to TREAKISYM® (bendamustine hydrochloride injection) in Japan, SymBio hascompleted consultations with the PMDA (Pharmaceuticals and Medical Devices Agency) on thecontent of the application for marketing authorization for RTD and the design of clinical trials for RI.
SymBio aims to launch these liquid formulations in Japan in or after FY2021. In addition, SymBio isconducting Phase 3 trials for the indication of diffuse large B-cell lymphoma (DLBCL), which accounts
for approximately one-third of malignant lymphoma, and aims to obtain approval for
relapsed/refractory DLBCL in the first half of fiscal 2021. SymBio will continue to steadily implement
these initiatives and maximize the business value of TREAKISYM® through appropriate life cycle
management and the patent protected liquid formulations.
There is no change to the Company’s earnings forecast for the year ended December 31, 2018.

1

(*)Please refer to SymBio’s IR News "Eagle Pharmaceuticals Licenses Japanese Rights for
Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio
Pharmaceuticals Limited" issued on September 21, 2017 for the conclusion of a licensing agreementwith Eagle.
http://www.symbiopharma.com/news_e/20170921_1e.pdf

About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectableproducts that address the shortcomings, as identified by physicians, pharmacists and otherstakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize theFDA's 505(b)(2) regulatory pathway. Additional information is available on the Company’s website atwww.eagleus.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., SymBio
Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medical
needs with main therapeutic focus in oncology, hematology and pain management.

2